Allogene gets FDA go-ahead to start ‘off-the-shelf’ CAR-T study in lymphoma
The Phase I study is planned to enroll 24 patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma and will be run under Allogene's collaboration with Servier.